evaluated. One of the compounds, N‐(6‐phenylheptyl)demethylvancomycin (12 a), was found to exhibit more potent antibacterial activity than vancomycin and demethylvancomycin. Compound 12 a was also found to be ∼18‐fold more efficacious than vancomycin against MRSA; however, the two compounds were found to have similar efficacy against MRS. Furthermore, compound 12 a exhibited a favorable pharmacokinetic profile
通过使用基于结构的方法,合理设计和合成了五种新颖的N-取代的脱甲基
万古霉素衍
生物。评估了对耐
甲氧西林金黄色葡萄球菌(MRSA),耐
庆大霉素的粪便肠球菌(GRE),耐
甲氧西林的肺炎链球菌(MRS)和耐
万古霉素的粪便肠球菌(VRE)的体外抗菌活性。发现其中一种化合物N-(6-苯基庚基)脱甲基
万古霉素(12 a)比
万古霉素和脱甲基
万古霉素显示出更强的抗菌活性。化合物12 a还发现抗MRSA的效力比
万古霉素高约18倍;但是,发现这两种化合物对MRS的疗效相似。此外,化合物12中的表现出有利的药物动力学轮廓具有5.11±0.52小时的半衰期,这比
万古霉素(4.3±1.9 H)的长。这些结果表明12 a是用于进一步临床前评估的有希望的抗菌药物候选物。